RMD — ResMed Inc. stock price and chart

RMD

ResMed Inc.Stock · HealthcareS&P 500 Equal Weight 0.2% · S&P 500 0.04% · Russell 1000 0.04% · Russell 3000 0.04% · US Stock Market 0.04% · MSCI ACWI 0.03% · MSCI World 0.03%

$218.27-0.60%

as of market close, Sep 11, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKABBV

Technical analysis2

Overlay lines0

Addendum charts0

VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDD

20162019202120242026

60.080.0100.0120.0140.0160.0180.0200.0220.0240.0260.0280.0020.0M$218.27

2026-09-11

Price$218.27

MA20$211.28

MA50$240.56

Vol7.3M

What would $1,000 invested in RMD be worth today? →

RMD returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $218.27
Change YTD: -8.64%
Next earnings: Oct 29, 2026
Market cap: 31.5B2016-09 9.1B2026-09 31.5B+244.7% over the window
Enterprise value: 30.8B
Shares outstanding: 144.3M2016-06 140.7M2026-06 144.3M+2.5% over the window
52W low: $180.27
52W high: $284.87
From 52W high: -23.38%
From 52W low: +21.08%
52W range: 36%
Beta: 0.75

Volume

Rel volume: 0.59×
30D volume: 1.5M
30D $ vol: 329.9M

Fundamentals

Sales (ttm): 5.7B2016-06 1.8B2026-06 5.7B+207.5% over the window
Sales/share: $39.192016-06 $13.072026-06 $39.19+199.9% over the window
EPS (ttm): $10.432016-06 $2.492026-06 $10.43+318.9% over the window
FCF (ttm): 1.6B2016-06 489.4M2026-06 1.6B+237.1% over the window
FCF/share: $11.442016-06 $3.482026-06 $11.44+228.8% over the window
Book value/share: $45.652016-06 $12.052026-06 $45.65+279.0% over the window
Net margin: 26.94%2016-06 19.2%2026-06 26.9%+40.6% over the window
ROE: 23.13%2016-06 20.8%2026-06 23.1%+11.2% over the window
ROA: 16.99%2016-06 10.8%2026-06 17.0%+57.0% over the window
Debt / equity: 0.06×2016-06 0.522026-06 0.06-88.2% over the window
Current ratio: 3.102016-06 2.232026-06 3.10+39.3% over the window

Growth (CAGR, ttm) · 10Y

Sales: +9.86%2025-06-30 → 2026-06-305.1B → 5.7B (+9.9% total)+10.21%2023-06-30 → 2026-06-304.2B → 5.7B (+33.9% total)+12.08%2021-06-30 → 2026-06-303.2B → 5.7B (+76.8% total)+11.89%2016-06-30 → 2026-06-301.8B → 5.7B (+207.5% total)
Net income: +8.76%2025-06-30 → 2026-06-301.4B → 1.5B (+8.8% total)+19.28%2023-06-30 → 2026-06-30897.6M → 1.5B (+69.7% total)+26.28%2021-06-30 → 2026-06-30474.5M → 1.5B (+221.0% total)+15.77%2016-06-30 → 2026-06-30352.4M → 1.5B (+332.3% total)
FCF: -0.73%2025-06-30 → 2026-06-301.7B → 1.6B (-0.7% total)+42.19%2023-06-30 → 2026-06-30573.6M → 1.6B (+187.6% total)+21.08%2021-06-30 → 2026-06-30634M → 1.6B (+160.2% total)+12.92%2016-06-30 → 2026-06-30489.4M → 1.6B (+237.1% total)
Shares: -1.48%2025-06-30 → 2026-06-30146.4M → 144.3M (-1.5% total)-0.64%2023-06-30 → 2026-06-30147.1M → 144.3M (-1.9% total)-0.20%2021-06-30 → 2026-06-30145.7M → 144.3M (-1.0% total)+0.25%2016-06-30 → 2026-06-30140.7M → 144.3M (+2.5% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: +9.68%2025-06-30 → 2026-06-30$9.51 → $10.43 (+9.7% total)+19.64%2023-06-30 → 2026-06-30$6.09 → $10.43 (+71.3% total)+26.35%2021-06-30 → 2026-06-30$3.24 → $10.43 (+221.9% total)+15.40%2016-06-30 → 2026-06-30$2.49 → $10.43 (+318.9% total)
Sales/share: +11.51%2025-06-30 → 2026-06-30$35.15 → $39.19 (+11.5% total)+10.92%2023-06-30 → 2026-06-30$28.71 → $39.19 (+36.5% total)+12.30%2021-06-30 → 2026-06-30$21.94 → $39.19 (+78.6% total)+11.61%2016-06-30 → 2026-06-30$13.07 → $39.19 (+199.9% total)
FCF/share: +0.76%2025-06-30 → 2026-06-30$11.35 → $11.44 (+0.8% total)+43.11%2023-06-30 → 2026-06-30$3.90 → $11.44 (+193.2% total)+21.32%2021-06-30 → 2026-06-30$4.35 → $11.44 (+162.8% total)+12.64%2016-06-30 → 2026-06-30$3.48 → $11.44 (+228.8% total)
Book value/share: +12.01%2025-06-30 → 2026-06-30$40.76 → $45.65 (+12.0% total)+17.58%2023-06-30 → 2026-06-30$28.08 → $45.65 (+62.6% total)+18.18%2021-06-30 → 2026-06-30$19.81 → $45.65 (+130.5% total)+14.25%2016-06-30 → 2026-06-30$12.05 → $45.65 (+279.0% total)
Dividend/share: +13.22%2025-06-30 → 2026-06-30$2.12 → $2.40 (+13.2% total)+10.89%2023-06-30 → 2026-06-30$1.76 → $2.40 (+36.4% total)+9.00%2021-06-30 → 2026-06-30$1.56 → $2.40 (+53.8% total)+7.18%2016-06-30 → 2026-06-30$1.20 → $2.40 (+100.0% total)
Price: -20.53%2025-09-11 → 2026-09-11$274.61 → $218.27 (-20.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+12.94%2023-09-11 → 2026-09-11$151.51 → $218.27 (+44.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-5.88%2021-09-10 → 2026-09-11$295.59 → $218.27 (-26.2% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+12.79%2016-09-09 → 2026-09-11$65.45 → $218.27 (+233.5% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: -19.69%2025-09-11 → 2026-09-11$271.74 → $218.27 (-19.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+14.05%2023-09-11 → 2026-09-11$147.10 → $218.27 (+48.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-5.02%2021-09-10 → 2026-09-11$282.47 → $218.27 (-22.7% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+14.05%2016-09-09 → 2026-09-11$58.59 → $218.27 (+272.5% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 20.9×2016-09 26.432026-09 20.67-21.8% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 16.7×2016-09 21.492026-09 16.69-22.3% over the window
Fwd P/E: 16.7×
P/S (ttm)Market cap ÷ TTM revenue.: 5.6×2016-09 4.972026-09 5.57+12.1% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 4.8×2016-09 5.152026-09 4.78-7.2% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 19.1×2016-09 20.172026-09 19.09-5.4% over the window
EV/EBITDA (fy): 14.8×
EV/Sales (ttm): 5.5×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 5.24%2016-06 5.4%2026-06 5.9%+9.5% over the window
Dividend yield (fwd)Indicated forward annual dividend ÷ current price — the rate the company has announced, not what was actually paid over the past year.: 1.10%
Dividend/share (fwd): $2.40
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 144.3M ÷ 146.4M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: 1.48%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (1.48%) + dividends paid over that year ($349.7M) ÷ market_cap_at(2025-06-30) ($37.8B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: 2.40%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($625.5M) ÷ today's market cap ($31.5B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 1.99%2016-06 0.8%2026-06 2.2%+173.2% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $625.5M + TTM dividends $349.7M) ÷ today's market cap ($31.5B). Same caveat as the cash buyback yield.: 3.10%2016-06 2.7%2026-06 3.5%+30.6% over the window

Vs own 10Y history

P/E: 3rd
P/OI: 3rd
P/S: 16th
P/B: 4th
P/FCF: 6th

Bar = where today’s multiple sits in RMD’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · windows as of 2026-09-11

-0.60%

-4.76%

-3.14%

+13.78%

YTD

-8.64%

-18.45%

-22.41%

Financial statements

Open full RMD financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	-8.44%	-0.65%
JNJ	Johnson & Johnson	+2.31%	-0.29%
ABBV	AbbVie Inc.	+3.36%	+0.83%
MRK	Merck & Co. Inc.	+8.28%	-0.54%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	-6.53%	-2.37%
TMO	Thermo Fisher Scientific Inc.	+1.13%	+1.10%
AMGN	Amgen Inc.	-8.80%	-1.34%
GILD	Gilead Sciences Inc.	+5.78%	-0.75%

ResMed Inc. (RMD) trades at $218.27 with a live price and an interactive chart covering 31+ years of daily price history, plus key valuation metrics. ChartRow also publishes RMD’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full RMD financial statements →

RMD — ResMed Inc. price, chart and key statistics